期刊文献+

术前希罗达化疗对大肠癌组织TP/PD-ECGF表达和血管生成的影响 被引量:7

Effect of preoperative chemotherapy on expression of TP/PD-ECGF and angiogenesis in colon cancer tissues
下载PDF
导出
摘要 目的研究术前希罗达化疗对大肠癌胸苷磷酸化酶血小板衍化内皮细胞生长因子(TP/PD-ECGF)和肿瘤组织微血管密度(MVD)的影响。方法对30例术前应用希罗达化疗的大肠癌和30例术前未化疗的大肠癌组织,采用免疫组织化学检测TP/PD-ECGF表达及微血管密度。结果术前化疗组TP PD ECGF表达阳性率为35.0%,对照组为63.0%;化疗组和对照组MVD值分别为37.4±18.0和65.8±12.5,差异有显著性。结论术前化疗能使TP PD ECGF活性降低,从而抑制大肠癌的肿瘤血管生成。 Objective To study the effect of preoperative chemotherapy with 5-DFUR on the expression of TP/PD-ECGF (thymidine phosphorylase/platelet-derived endothelial cell growth factor) and MVD (microvessel density) in colon cancer tissues.Methods Thirty cases receiving preoperative 5-DFUR chemotherapy and 30 cases without preoperative chemotherapy were analyzed.Immunohistochemical staining was performed using CD34^+ and TP/PD-ECGF monoclonal antibodies to detect MVD and TP/PD-ECGF expression.Results The positive expression rate of TP/PD-ECGF was (35.0%) and 63.0% in chemotherapy group and control group respectively. MVD was 37.4±18.0 in chemotherapy group and 65.8±12.5 in control group.There was statistical significance in expression of TP/PD-ECGF and MVD between two groups.Conclusion Preoperative chemotherapy can decrease the activity of TP/PD-DCGF and inhibit the angiogenesis of colon cancer.
出处 《中国肿瘤临床与康复》 2005年第2期97-99,共3页 Chinese Journal of Clinical Oncology and Rehabilitation
关键词 结直肠肿瘤 胸苷磷酸化酶/血小板衍化内皮细胞生长因子 微血管密度 希罗达 Colorectal neoplasms Thymidine phosphorylase/platelet-derived endothelial cell growth factor (TP/PD-ECGF) Microvessel density(MVD) 5'-DFUR
  • 相关文献

参考文献6

  • 1王宝成,毕经旺,李志.靶向化疗——氟化嘧啶类药物的研究进展[J].国外医学(肿瘤学分册),2001,28(6):447-451. 被引量:73
  • 2Mattern J,Koommagi R,Volm M. Biological characterization of subgroups of squamous cell lung carcinomas[J].Clin Cancer Res,1999,5(6): 1459.
  • 3Miwa M,Ura M,Nishida M,et al. Design of novel oral fluoropyrimidine carbamate capecitabine,which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue[J].Eur J Cancer,1998,34(8):1274.
  • 4Koizumi W,Salgenji K,Nakamaru N,et al. Prediction of response to 5-deoxy-5-fluorouridine (5-DFUR) in patients with inoperable advance gastric cancer by immunostaining of thymidine phosphorylase/platelet-derived endothelial cell growth factor[J]. Oncology,1999,56(3):215.
  • 5Okamoto E,Osaki M,Kase S,et al. Thymidine phosphorylase expression causes both the increase of intratumoral microvessel and decrease of apoptosis in human esophageal carcinomas[J].Pathology,2001,51(3):158.
  • 6Semiglazova TU,Gershanovlch ML. Xeloda(capecetabine) in the treatment of disseminated breast cancer after failure with anthracyclines and taxanes[J].Voprosy Oncology,2001,47(3):298.

二级参考文献16

  • 1Koizumi W, Saigenji K, Nakamaru N,et al. Prediction of response to 5'-deoxy-5-fluorouridine (5'-DFUR) in patients with inoperable advanced gastric cancer by immunostaining of thymidine phosphorylase/platelet-derived endothelial cell growth factor [J]. Oncology,1999;56(3) :215-222.
  • 2Takiguchi N, Nakajima N, Saitoh N, et al. A phase Ⅲ randomized study comparing oral doxifluridine and oral 5-fluorouracil after curative resection of gastric cancer[J]. Int J Oncol, 2000 , 6 (5): 1021-1027.
  • 3Miyadera K, Sumizawa T, Haraguchi M, et al . Role of thymidine phosphorylase activity in the angiogenic effect of platelet derived endothelial cell growth factor/thymidine phosphorylase[J]. Cancer Res,1995,55(8): 1687-1690.
  • 4Maeda K, Chung YS, Ogawa Y, et al. Thymidine phosphorylase/platelet-derived endothelial cell growth factor expression associated with hepatic metastasis in gastric carcinoma[J]. Br J Cancer, 1996,73 (8): 884-888.
  • 5Mata JF, Garcia Manteiga JM, Lostao MP, et al. Role of the human concentrative nucleoside transporter (hCNT1) in the cytotoxic action of 5 [Prime] - deoxy- 5- fluorouridine, an active intermediate metabolite of capecitabine, a novel oral anticancer drug[J ]. Mol Pharmacol,2001,59(6): 1542.
  • 6Miwa M, UraM, NishidaM, etal. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue[J]. Eur J Cancer, 1998,34(8) :1274-1281.
  • 7Reigner B, Blesch K, Weidekamm E. Clinical pharmacokinetics of capecitabine[J]. Clin Pharmacokinet,2001,40(2) :85-104.
  • 8Blum JL, Jones SE, Buxdar AU, et al. Multicenter phase Ⅱ study of capecitabine in paclitaxel-refractory metastatic breast cancer[J]. J Clin Oncol, 1999,17 ( 2): 485 -493.
  • 9O'shaughnessy J, Moiseyenko V, Bell D, et al. A randomized phase Ⅱ study of Xeloda (capecitabine) vs CMF as first line chemotherapy of breast cancer in women aged≥55 years[J]. Proc Am Soc Clin Oncol, 1998,17:398-406.
  • 10O'Reilly SM,Moiseyenko V,Talbot DC, et al. A randomized phase Ⅱ study of Xeloda (capecitabine)vs paclitaxel in breast cancer patients failing previous anthracycline therapy[J]. Proc Am Soc Clin Oncol, 1998,17: 627-635.

共引文献72

同被引文献79

引证文献7

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部